Ken Griffin
MRKR icon

Ken Griffin’s Marker Therapeutics MRKR Stock Holding History

Ken Griffin’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,847
Closed -$87.7K – 13752
2025
Q4 		$87.7K Buy
+58,847
New +$66.6K ﹤0.01% 11738
2024
Q4 		– Sell
-13,032
Closed -$36.8K – 15069
2024
Q3 		$36.8K Buy
+13,032
New +$51.5K ﹤0.01% 12241
2022
Q3 		– Sell
-14,432
Closed -$48K – 13240
2022
Q2 		$48K Buy
+14,432
New +$48K ﹤0.01% 11962
2022
Q1 		– Sell
-1,651
Closed -$9.44K – 14221
2021
Q4 		$16K Sell
1,651
-616
-27% -$8.18K ﹤0.01% 13619
2021
Q3 		$38K Sell
2,267
-27,036
-92% -$554K ﹤0.01% 13488
2021
Q2 		$817K Buy
29,303
+11,132
+61% +$293K ﹤0.01% 8893
2021
Q1 		$407K Buy
18,171
+13,517
+290% +$309K ﹤0.01% 10139
2020
Q4 		$67K Sell
4,654
-220
-5% -$3.42K ﹤0.01% 10445
2020
Q3 		$73K Buy
4,874
+106
+2% +$1.93K ﹤0.01% 9442
2020
Q2 		$99K Sell
4,768
-1,612
-25% -$35.3K ﹤0.01% 8998
2020
Q1 		$121K Buy
+6,380
New +$163K ﹤0.01% 8485
2019
Q4 		– Sell
-8,761
Closed -$448K – 9504
2019
Q3 		$448K Buy
+8,761
New +$518K ﹤0.01% 6936

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Ken Griffin's MRKR Position: Q1 2026 in Review

Ken Griffin sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 58,847 shares — an estimated $87.7K sold.

Ken Griffin first reported a position in MRKR in Q3 2019 and held it in 12 quarters. The position peaked at $817K in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Ken Griffin reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 58,847 Marker Therapeutics shares in Q1 2026, an estimated $87.7K.
  • Ken Griffin first reported a position in Marker Therapeutics in Q3 2019 and held it in 12 quarters.
  • Ken Griffin's Marker Therapeutics position peaked at $817K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.